Vanguard Asset Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
BBA
Vanguard Asset Management's GLUE Position: Q3 2026 in Review
Vanguard Asset Management held its Monte Rosa Therapeutics (GLUE) position steady in Q3 2026 at 33,732 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #2262.
Vanguard Asset Management first reported a position in GLUE in Q1 2026 and has held it in 3 quarters since. The position peaked at $816K in Q2 2026. 190 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- Vanguard Asset Management held 33,732 shares of Monte Rosa Therapeutics worth $402K as of Q3 2026.
- Vanguard Asset Management left its Monte Rosa Therapeutics share count unchanged in Q3 2026.
- Monte Rosa Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #2262 holding.
- Vanguard Asset Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Asset Management's Monte Rosa Therapeutics position peaked at $816K in Q2 2026.
- 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.